Comparison of clinical and laboratory features at initial diagnosis of 463 ALCL99 patients according to stage of disease
| . | Stage I (n = 36) . | Stage II (n = 78) . | Stage III/IV (n = 349) . | P, I vs II vs III/IV . |
|---|---|---|---|---|
| Male sex, n (%) | 20 (56) | 49 (63) | 213 (61) | .76 |
| Mean age at biopsy,y (±SD) | 11.2 ± 4.1 | 11.0 ± 3.9 | 10.2 ± 4.5 | .21 |
| Histologic subtype: LH/SC/mixed ALCL, n (%) | 8 (23) | 15 (21) | 106 (33) | .08 |
| Immunophenotype, n (%) | ||||
| ALK+ | 31 (86) | 75 (96) | 335 (96) | .05 |
| Cell lineage, n (%) | ||||
| Null | 5 (14) | 12 (15) | 39 (11) | .49 |
| T | 31 (86) | 66 (85) | 310 (89) | |
| B-symptoms, n (%) | 4 (11) | 21 (27) | 234 (68) | < .0001 |
| Localization, n (%) | ||||
| Lymph node | 26 (72) | 72 (92) | 301 (86) | .02 |
| Soft tissue | 8 (22) | 15 (19) | 51 (15) | .34 |
| Bone lesion | 4* (11) | 6 (8) | 67 (23) | .008 |
| LDH (before treatment), U/L | 314 (±232) | 366 (±216) | 563 (±651) | .004 |
| . | Stage I (n = 36) . | Stage II (n = 78) . | Stage III/IV (n = 349) . | P, I vs II vs III/IV . |
|---|---|---|---|---|
| Male sex, n (%) | 20 (56) | 49 (63) | 213 (61) | .76 |
| Mean age at biopsy,y (±SD) | 11.2 ± 4.1 | 11.0 ± 3.9 | 10.2 ± 4.5 | .21 |
| Histologic subtype: LH/SC/mixed ALCL, n (%) | 8 (23) | 15 (21) | 106 (33) | .08 |
| Immunophenotype, n (%) | ||||
| ALK+ | 31 (86) | 75 (96) | 335 (96) | .05 |
| Cell lineage, n (%) | ||||
| Null | 5 (14) | 12 (15) | 39 (11) | .49 |
| T | 31 (86) | 66 (85) | 310 (89) | |
| B-symptoms, n (%) | 4 (11) | 21 (27) | 234 (68) | < .0001 |
| Localization, n (%) | ||||
| Lymph node | 26 (72) | 72 (92) | 301 (86) | .02 |
| Soft tissue | 8 (22) | 15 (19) | 51 (15) | .34 |
| Bone lesion | 4* (11) | 6 (8) | 67 (23) | .008 |
| LDH (before treatment), U/L | 314 (±232) | 366 (±216) | 563 (±651) | .004 |
LH indicates lymphohistiocytic variant; SC, small cell variant; mixed ALCL, LH and/or SC component; and LDH, lactate dehydrogenase.
Of the 4 patients,1 had solitary bone disease and 3 had a concomitant soft tissue mass.